ZipPrime
Private Company
Funding information not available
Overview
ZipPrime is an R&D-focused biotech firm addressing critical pre-analytical challenges in liquid biopsy workflows. Its core innovation is a novel cfDNA capturing and preservation technology inspired by intracellular DNA recognition pathways, which tags individual cfDNA molecules to prevent loss and enable reusable storage. This platform-independent solution is positioned as a sample preparation kit for clinicians and researchers, compatible with standard PCR and NGS tools. The company targets the growing market for non-invasive, early cancer diagnostics by improving the sensitivity and reliability of cfDNA biomarker detection.
Technology Platform
Patented, integrated platform for single-molecule-level capture, detection, and reusable preservation of circulating free DNA (cfDNA). Inspired by intracellular DNA recognition pathways, it uses a tagging mechanism to prevent biomarker loss and create a re-usable cfDNA library compatible with PCR and NGS.
Opportunities
Risk Factors
Competitive Landscape
ZipPrime competes with established life science tools companies (e.g., Qiagen, Roche, Thermo Fisher) that offer cfDNA extraction kits, often based on size-selection or bead-based methods. Its key differentiators are the claimed single-molecule capture efficiency and the unique ability to create a reusable, preservable cfDNA biomarker library, a feature not commonly offered by incumbents.